|Videos|August 19, 2021
Deep Dive: Deep Dive Into Bevacizumab Biosimilars for Eye Conditions
As use of reference bevacizumab (Avastin) for the treatment of macular degeneration has increased over the past decade, payers have begun to recommend bevacizumab biosimilars for the same indication. However, some institutions, including the American Academy of Ophthalmology, say that there needs to be more evidence for the use of these biosimilars for macular degeneration and that recommending them for use is premature.
Related Articles
- Deep Dive: Into AI Tech and Coughing
June 19th 2023
- Behind the Science: Behind AI in Colorectal Cancer
May 17th 2023
- Deep Dive: Into the Rise of AI in Oncologic Care
May 17th 2023
- Deep Dive: Into ChatGPT and Generative AI
April 28th 2023
- Behind the Science: Behind ChatGPT in Radiology
April 27th 2023
- Deep Dive: Into Psychedelic Treatments
April 14th 2023